Rebiotix, one of a handful of major companies working on microbiome-based drugs, announced Wednesday that its donor stool-based therapeutic for deadly Clostridium difficile infections was successful — the first-ever unveiling of positive Phase 3 data for any company in the nascent microbiome industry.
The drug, which is delivered as an enema, significantly reduced the number of people who had diarrhea within eight weeks of their treatment, which is one sign that a C. difficile infection may be recurring, the company said. But the data are incredibly limited — they don’t show comparison to placebo group or other relative metrics. Rebiotix, which is owned by Ferring Pharmaceuticals, based the results on a preliminary analysis which did not include any other data or detailed statistics.
About the Author Reprints
